PharmaSUG 2026 - Paper SS-193

Structure for Success: Delivering a Complex, Accelerated NDA with Evolving Scope

Tingting Tian, Chao Su and Erica Davis, Merck & Co., Inc., Rahway, NJ, USA

ABSTRACT

Late-stage regulatory submissions such as New Drug Applications (NDAs) require tight coordination among clinical, statistical, programming, and other functional teams, while timelines and scope evolve in real time. This paper describes the planning, execution, and lessons learned from an NDA comprising nine components: a supportive Phase II study, four pivotal Phase III studies, three pooling packages, and a combined BIMO package. Approximately 1,300 tables, figures, and listings (TFLs) were produced, with a Safety Update Report (SUR) following. Timelines for each of the Phase III database locks and the target submission date shifted earlier by 2-5 months, reducing development and review cycles.

Key challenges included managing a compressed and shifting timeline, incorporating late-breaking requests for an Integrated Summary of Efficacy, and extensive post-hoc sensitivity analyses, and delivering complex model-based efficacy analyses that required advanced handling and computationally intensive methods.

To address these challenges, the team implemented staggered development, centralized standards under a lead statistical programmer, regularly scheduled cross-functional check-ins, automation-enabled QC, structured intake and prioritization of post-DBL requests, and enhanced validation strategies such as four-way validation. The paper concludes with practical recommendations on minimum development windows, risk-based dry runs, modular programming standards, and governance of resources and requests for accelerated submissions.

INTRODUCTION

Late-stage regulatory submissions are inherently complex, requiring coordination across multiple functional areas under strict timelines. For this NDA, the scope was particularly challenging: nine submission packages comprising one Phase II study, four pivotal Phase III studies, three pooling packages, and one combined BIMO package. In total, approximately 1,300 tables, figures, and listings (TFLs) were generated. Additionally, a Safety Update Report (SUR) was planned for submission the following year.

The original submission target was accelerated by following multiple planning sessions, compressing development timelines and increasing operational risk. This paper outlines the challenges encountered, solutions implemented, and lessons learned during this process.

OVERVIEW OF SUBMISSION PACKAGES

The NDA submission included:

- **Phase II Study:** Two packages (interim and final) provided supportive efficacy and safety data.
- **Four Phase III Studies:** Core evidence for indication approval.
- **Three Pooling Packages:** Integrated safety and efficacy summaries.
- **Combined BIMO Package:** Supported FDA's site-level inspections

A timeline diagram (Figure 1) illustrates overlapping preparation periods for key Phase III studies. Database lock (DBL) dates advanced by 2–5 months, leaving minimal sequencing windows between Clinical Study Report (CSR) completion and submission deliverables. This overlap placed significant pressure on programming and statistical teams, requiring parallel development of multiple packages.



Figure 1 Pivotal studies DBL and CSR dates

KEY CHALLENGES

1. Timeline Management

The most pressing challenge was accelerated timelines. DBLs advanced by up to five months, compressing sequencing and review windows andre forcing reliance on partial dry runs and creating heavy resource strain. Overlapping review cycles across deliverables left little time to incorporate team feedback, and shared resources across projects amplified the pressure.

2. Late-Breaking Requests

Several unplanned analyses emerged post-DBL:

- An unplanned efficacy analysis
- Three new integrated analyses requested after DBL.
- Need for an Integrated Summary of Efficacy (ISE) identified after pivotal studies achieved DBL.
- Lack of advance planning for primary publications triggered a wave of post-hoc sensitivity analyses across multiple reports, stretching unblinded resources during critical periods.

3. Complex Efficacy Analyses

A novel model-based efficacy approach was required for pivotal studies, requiring bespoke processes and extensive validation. Computational demands were significant:

- LDL-C beta-quantification and Martin-Hopkins selection rules.
- Handling anomalies such as “<0” values.
- Bootstrap imputation involving 1,000 samples × 100 imputations. Disease-specific TF formats added another layer of complexity, requiring custom solutions for consistency and compliance.

SOLUTIONS IMPLEMENTED

1. Timeline Management

To execute, the team shifted from a sequential workflow to a submission-spanning pipeline with explicit gates. Key practices included:

- **Staggered development:** earlier packages served as test cases to stabilize templates and reduce rework for later packages.
- **Dedicated leadership:** a single lead statistical programmer owned cross-package standards, consistency, and escalation.

- **Routine cross-functional check-ins:** short, regular touchpoints between Statistics and Statistical Programming maintained alignment and resolved decisions quickly.
- **Proactive resource allocation:** resource adjustments during peak periods were driven by an integrated view of study/package milestones and key priorities.
- **Centralization of study information and strong documentation:** A SharePoint site containing background information, team decisions, and critical dates for each study was made accessible to all team members. Program trackers and ad-hoc trackers were created to document requests, timelines, required summaries, and assigned staff, enabling effective tracking of task progress and status.

Operationally, the pipeline approach emphasized early stabilization of shells, display conventions, and derivation rules, coupled with a decision log owned by Statistics and Programming leads. Outputs entered formal review only after meeting defined “review-ready” criteria (QC checks passed, traceability updated, and key decisions documented).

2. Automation-enabled QC as an early gate

Automation-enabled QC was used to detect repeatable failure modes before outputs entered formal review.

Rather than replace human review, automated checks served as a consistency gate for high-volume production. Typical checks included:

- **SAS log cleanliness** (e.g., warnings or errors in ADaM/TLF program logs)
- **Display conformance** (e.g., titles/footnotes, table margin)
- **Consistency across packages** (variables attributes between/Within SDTM and ADaM datasets)
- **Traceability/metadata alignment** (output identifiers, spec linkage, time stamps)

This approach improved review efficiency by preventing avoidable formatting and consistency defects from reaching reviewers, allowing review effort to focus on scientific and statistical accuracy.

3. Handling Late-Breaking Requests

To manage scope volatility, the team implemented structured request intake and prioritization:

- **Single intake channel and standardized request template** (driver, impacted outputs, acceptance criteria, risk level)
- **Triage and prioritization** by Statistics and Programming leads
- **Post-DBL quality sweeps** to surface high-risk issues early
- **Reusable templates and macros** to reduce turnaround time for late additions

This governance reduced churn by making scope decisions explicit, traceable, and aligned with the submission critical path.

4. Managing Complex Efficacy

For novel efficacy, validation was strengthened beyond standard approaches. A four-way validation model (One statistician and one programmer will develop independently, while another statistician and one programmer will validate independently, and the team will reconcile any discrepancies together.) improved defect detection and reduced the likelihood of shared-assumption errors.

A pre-DBL derivation review by an unmasked statistician reduced downstream rework.

Preprocessing rules were documented as a “data contract” to ensure reproducibility for primary endpoint data selection and anomaly handling.

Monthly Data Management reviews tracked unresolved data issues and documented their impact on primary endpoints.

LESSONS LEARNED

1. **Advance Timeline Planning**

To deliver 10 ADaM eSub packages with high quality, early timeline planning for each study is essential. Establish minimum development timelines and fallback schedules early to mitigate risks and prevent last-minute scrambles.

2. **Comprehensive Dry Runs**

Full dry runs are ideal; if only partial dry runs are feasible, focus on the highest-risk summaries and targeted manual checks in addition to standard quality control for lower-risk items.

3. **Modular Standards & Risk Management**

Establishing modular standards upfront to reduce rework and empower leads to escalate risks promptly.

4. **Resource Planning & Rapid Response**

Use a transparent intake queue, triage rules, and a small rapid-response pod (Statistics, Programming, QC) during peak periods to absorb high-impact late requests (e.g., integrated summaries) without derailing core production. Assigning a lead for each study and each task is also important to ensure quick responses and achieve our goals.

CONCLUSION

This NDA submission demonstrated that accelerated timelines and complex analyses can be managed successfully through proactive planning, robust validation strategies, and strong cross-functional collaboration. Key enablers included staggered development, reusable tools, and transparent prioritization frameworks. These lessons provide a roadmap for future submissions facing similar challenges.

ACKNOWLEDGMENTS

The authors would like to thank their management for their support and encouragement.

CONTACT INFORMATION

Your comments and questions are valued and encouraged. Contact the authors at:

Tingting Tian	Chao Su	Erica Davis
+1 (732) 5942049	+1 (732) 5946459	+1 (732) 5941383
tingting.tian@merck.com	chao.su@merck.com	erica.davis1@merck.com